ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1993

Contribution of Lifestyle Factors to Healthy-Adherer Bias in Prevalent Users of Osteoporotic Drugs

Mitsuyo Kinjo1 and Daniel H. Solomon2, 1Internal Medicine, Okinawa Chubu Hospital, Uruma City Okinawa, Japan, 2Division of Rheumatology, Brigham and Women's Hospital, Boston, MA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Health behaviors and osteoporosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Osteoporosis and Metabolic Bone Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Adherence to drug therapy may be a surrogate marker for overall healthy behaviors leading to healthy-adherer bias in epidemiologic studies. This might be particularly emphasized in osteoporosis supplements and medications. However, individual factors contributing to healthy-adherer effects and their quantitative impacts are not well described. We assessed the association between prevalent use of and adherence to osteoporotic supplements or medications and healthy lifestyle factors in a population-based sample from the National Health and Nutrition Examination Survey, 1999-2008.

Methods:

We identified subjects who used calcium plus vitamin D supplements and/or osteoporotic medications (bisphosophonate, calcitonin or raloxifene). We estimated the magnitude of association between prevalent use of these osteoporotic drugs and demographic, lifestyle and comorbid illness factors. Demographic, lifestyle, and comorbid factors of interest included body mass index, exercise, smoking, alcohol consumption, self-reported health status, comorbidities (cancer, coronary artery disease, COPD and diabetes), and steroid use. We also examined the subset of subjects with a history of fracture in the hip, wrist or spine, or those with osteoporosis who were advised to take treatments.

Results:

Among 25,290 subjects, 1,529 were users and 23,761 were nonusers of calcium, vitamin D or an osteoporosis medication. Users and nonusers were similar in age (mean age 57 years), but were more likely to be women (64% vs 52%; P < .05). After adjustment for age, prevalent female users 50 years or older had significantly less severe obesity (odds ratio 0.7, 95% CI: 0.6, 0.9), current or past smoking (OR 0.8, 95% CI: 0.5, 1.0), more moderate exercise (OR 1.4, 95% CI:1.1, 1.8), lower self-reported poor health (OR 0.8, 95% CI: 0.7, 0.9), less diabetes (OR 0.7, 95% CI:0.6, 0.9) and acute coronary syndrome (OR 0.8, 95% CI:0.7, 1.0). Among subjects with previous fracture or osteoporosis, a similar trend was seen between users and nonusers.

Conclusion:

In a large representative US population, prevalent use or adherence to osteoporotic drugs was associated with healthier lifestyle factors. The results suggest that healthy user or adherer can be explained, in part, by the healthier lifestyles in prevalent users or adherers in the elderly.


Disclosure:

M. Kinjo,
None;

D. H. Solomon,

Amgen & Lilly,

2,

Corrona,

5,

Pfizer Inc,

9.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/contribution-of-lifestyle-factors-to-healthy-adherer-bias-in-prevalent-users-of-osteoporotic-drugs/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology